 |
 |
| Home |
| Clinical Trial Search |
| Mailing List |
| Clinical Trial FAQs |
| Participation FAQs |
| Clinical Trials Glossary |
| About Informed Consent |
| Medical Research Areas |
| Clinical Trial Links |
|
This site is intended for U.S. residents only. For Novartis Worldwide, Click here |
|
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
|
|
|
|
|||
Clinical Trial Search
Ovarian Cancer
Ovarian cancer occurs when cells grow in an uncontrolled, abnormal manner and produce tumors in one or both ovaries.
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. How to use this system:The purpose of this system is to help connect interested study participants with clinical research centers. The following is a brief outline explaining the main steps involved in using this system. Please note that every step in this process is optional.
1. Select a clinical trial that you feel best suits your (or the participant's)
health condition. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Ovarian Cancer Study CEPO906A2303
Novartis Oncology is conducting a clinical research study to find out if the study drug patupilone is safe, prolongs survival, and has any additional beneficial effects in patients with ovarian, primary fallopian, or primary peritoneal cancer who did not respond to chemotherapy or whose disease came back after chemotherapy. Pegylated liposomal doxorubicin is chemotherapy approved by the FDA for use in ovarian, primary fallopian, or primary peritoneal cancer and is a standard treatment for this type of cancer at this stage of the disease. Because we do not know which medicine is best, we need to make a comparison of the two products: pegylated liposomal doxorubicin and patupilone. Study patients may get either 10 mg/m2 patupilone once every three weeks or 50 mg/m2 of pegylated liposomal doxorubicin once every four weeks, intravenously (directly into a vein). Study patients will have a 50% chance of being assigned to receive either the study drug patupilone or pegylated liposomal doxorubicin. Patients are assigned to a particular treatment by an automatic system. Patients or doctors will not have a choice of which medication the patient will receive. The study drug, Patupilone, is a medicine which has not been approved by the FDA (US Food and Drug Administration) or the EMEA (European Medicines Agency).
Trial phase: Phase 3 Participation Duration: 1 hour visit to study site, every 3-4 wks for treatment and evaluations. After completion of study treatment, you will be asked to come to the study site every 3 months to see how you’re doing and follow the progress of your disease. Protocol Number: CEPO906A2303 |
